Vázquez Estévez, S.
Anido, U.
Lázaro, M.
Fernández, O.
Fernández Núñez, N.
de Dios Álvarez, N.
Varela, V.
Campos Balea, B.
Agraso, S.
Areses, M. C.
Iglesias, L.
Blanco, M.
Maciá, S. http://orcid.org/0000-0002-0533-8153
Anton Aparicio, L. M.
Funding for this research was provided by:
eusapharma
Article History
Received: 8 January 2020
Accepted: 9 January 2020
First Online: 15 February 2020
Compliance with ethical standards
:
: Dr. Martín Lázaro has been consultant for BMS, MSD, Takeda, Roche, Pfizer, Ipsen, Astra-Zeneca, Boehringer, Pierre-Fabre, Bayer. Has been speaker for Roche, Ipsen, Lilly, Astellas, Janssen, Novartis, Boehringer, Vifor. Has received grant or travel support from MSD, Ipsen, Roche, Janssen, Pfizer, Astellas, Pierre-Fabre. Dr. Anido Herranz reports non-financial support and other from Pfizer, personal fees, non-financial support and other from Novartis, non-financial support and other from Bayer, personal fees, non-financial support and other from Ipsen, other from EUSA, non-financial support and other from Sanofi, non-financial support and other from Advanced Accelerator Applications, grants and non-financial support from Pierre Fabre, personal fees and non-financial support from BMS, non-financial support from Roche, personal fees and non-financial support from Astellas, personal fees from Janssen, personal fees from Kyowa Kirin, personal fees from Lilly, outside the submitted work. Dr. Vázquez Estévez reports non-financial support and other from Pfizer, personal fees, non-financial support and other from Novartis, non-financial support and other from Bayer, personal fees, non-financial support and other from Ipsen, other from EUSA, non-financial support and other from Sanofi, grants and non-financial support from Pierre Fabre, personal fees and non-financial support from BMS, non-financial support from Roche, personal fees and non-financial support from Astellas, personal fees from Janssen. Dr. Fernández has had consultant or advisore role for Astellas Pharma, Roche, Pfizer, Bristol-Myers-Squibb, Sanofi, EUSA Pharma and Sanofi; has received honorari as speaker for Pierre-Fabre, Novartis, Bristol-Myers-Squibb, Ipsen, Roche, Astellas Pharma, Bayer and Janssen; has received travel/accommodations fees from Bristol-Myers-Squibb, Ipsen, Astellas. Rest of the authors have no relevant conflicts of interests.
: The manuscript does not contain clinical studies or patient data.
: Not applicable.